<antigenSupportingData>
<immunity>
</immunity>
<contraindications>
<vaccineGroup>
<contraindication>
<observationCode>080</observationCode>
<observationTitle>Adverse reaction to vaccine component</observationTitle>
<contraindicationText>Do not vaccinate if the patient has had an adverse reaction to a vaccine component.</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
<contraindication>
<observationCode>270</observationCode>
<observationTitle>Severe allergic reaction after previous dose of Chikungunya vaccine</observationTitle>
<contraindicationText>Do not vaccinate if the patient has had a severe allergic reaction after a previous dose of Chikungunya vaccine.</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
</vaccineGroup>
<vaccine>
<contraindication>
<observationCode>145</observationCode>
<observationTitle>B-lymphocyte [humoral] - Severe antibody deficiencies</observationTitle>
<contraindicationText>Do not vaccinate if the patient has severe B-lymphocyte (humoral) - antibody deficiencies (e.g., X-linked agammaglobulinemia and common variable immunodeficiency).</contraindicationText>
<contraindicationGuidance/>
<contraindicatedVaccine>
<vaccineType>Chikungunya live attenuated vaccine, 0.5 mL, PF</vaccineType>
<cvx>317</cvx>
<beginAge/>
<endAge/>
</contraindicatedVaccine>
</contraindication>
<contraindication>
<observationCode>146</observationCode>
<observationTitle>B-lymphocyte [humoral] - Less severe antibody deficiencies</observationTitle>
<contraindicationText>Do not vaccinate if the patient has less severe B-lymphocyte (humoral) - antibody deficiencies (e.g., selective IgA deficiency and IgG subclass deficiency).</contraindicationText>
<contraindicationGuidance/>
<contraindicatedVaccine>
<vaccineType>Chikungunya live attenuated vaccine, 0.5 mL, PF</vaccineType>
<cvx>317</cvx>
<beginAge/>
<endAge/>
</contraindicatedVaccine>
</contraindication>
<contraindication>
<observationCode>147</observationCode>
<observationTitle>T-lymphocyte [cell-mediated and humoral] - Complete defects</observationTitle>
<contraindicationText>Do not vaccinate if the patient has complete cell-mediated or humoral T-lymphocyte defects (e.g., severe combined immunodeficiency [SCID] disease, complete DiGeorge syndrome).</contraindicationText>
<contraindicationGuidance/>
<contraindicatedVaccine>
<vaccineType>Chikungunya live attenuated vaccine, 0.5 mL, PF</vaccineType>
<cvx>317</cvx>
<beginAge/>
<endAge/>
</contraindicatedVaccine>
</contraindication>
<contraindication>
<observationCode>148</observationCode>
<observationTitle>T-lymphocyte [cell-mediated and humoral] - Partial defects</observationTitle>
<contraindicationText>Do not vaccinate if the patient has partial cell-mediated or humoral T-lymphocyte defects (e.g., most patients with DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia).</contraindicationText>
<contraindicationGuidance/>
<contraindicatedVaccine>
<vaccineType>Chikungunya live attenuated vaccine, 0.5 mL, PF</vaccineType>
<cvx>317</cvx>
<beginAge/>
<endAge/>
</contraindicatedVaccine>
</contraindication>
<contraindication>
<observationCode>150</observationCode>
<observationTitle>T-lymphocyte [cell-mediated and humoral] - interferon-gamma or interferon-alpha</observationTitle>
<contraindicationText>Do not vaccinate if the patient has cell-mediated or humoral T-lymphocyte defects related to interferon-gamma or interferon-alpha</contraindicationText>
<contraindicationGuidance/>
<contraindicatedVaccine>
<vaccineType>Chikungunya live attenuated vaccine, 0.5 mL, PF</vaccineType>
<cvx>317</cvx>
<beginAge/>
<endAge/>
</contraindicatedVaccine>
</contraindication>
<contraindication>
<observationCode>153</observationCode>
<observationTitle>Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency</observationTitle>
<contraindicationText>Do not vaccinate if the patient has a phagocytic function defect (e.g. leukocyte adhesion defect and myeloperoxidase deficiency).</contraindicationText>
<contraindicationGuidance/>
<contraindicatedVaccine>
<vaccineType>Chikungunya live attenuated vaccine, 0.5 mL, PF</vaccineType>
<cvx>317</cvx>
<beginAge/>
<endAge/>
</contraindicatedVaccine>
</contraindication>
<contraindication>
<observationCode>154</observationCode>
<observationTitle>HIV/AIDS - severely immunocompromised</observationTitle>
<contraindicationText>Do not vaccinate if the patient has HIV/AIDS and is severely immunocompromised (See the CDC general recommendations for a definition of "severely immunocompromised").</contraindicationText>
<contraindicationGuidance/>
<contraindicatedVaccine>
<vaccineType>Chikungunya live attenuated vaccine, 0.5 mL, PF</vaccineType>
<cvx>317</cvx>
<beginAge/>
<endAge/>
</contraindicatedVaccine>
</contraindication>
<contraindication>
<observationCode>156</observationCode>
<observationTitle>Generalized malignant neoplasm</observationTitle>
<contraindicationText>Do not vaccinate if the patient has generalized malignant neoplasm.</contraindicationText>
<contraindicationGuidance/>
<contraindicatedVaccine>
<vaccineType>Chikungunya live attenuated vaccine, 0.5 mL, PF</vaccineType>
<cvx>317</cvx>
<beginAge/>
<endAge/>
</contraindicatedVaccine>
</contraindication>
<contraindication>
<observationCode>157</observationCode>
<observationTitle>Sold organ transplantation</observationTitle>
<contraindicationText>Do not vaccinate if the patient received a solid organ transplant.</contraindicationText>
<contraindicationGuidance>Certain immunosuppressive medications are administered to prevent solid organ transplant rejection. Live vaccines should be withheld for 2 months following discontinuation of anti-rejection therapies in patients with a solid organ transplant.</contraindicationGuidance>
<contraindicatedVaccine>
<vaccineType>Chikungunya live attenuated vaccine, 0.5 mL, PF</vaccineType>
<cvx>317</cvx>
<beginAge/>
<endAge/>
</contraindicatedVaccine>
</contraindication>
<contraindication>
<observationCode>158</observationCode>
<observationTitle>Immunosuppressive therapy</observationTitle>
<contraindicationText>Do not vaccinate if the patient is undergoing immunosuppressive therapy. Immunosuppressive medications include those given to prevent solid organ transplant rejection, human immune mediators like interleukins and colony-stimulating factors, immune modulators like levamisol and BCG bladder-tumor therapy, and medicines like tumor necrosis factor alpha inhibitors and anti-B cell antibodies. </contraindicationText>
<contraindicationGuidance/>
<contraindicatedVaccine>
<vaccineType>Chikungunya live attenuated vaccine, 0.5 mL, PF</vaccineType>
<cvx>317</cvx>
<beginAge/>
<endAge/>
</contraindicatedVaccine>
</contraindication>
<contraindication>
<observationCode>159</observationCode>
<observationTitle>Radiation therapy</observationTitle>
<contraindicationText>Do not vaccinate if the patient is undergoing radiation therapy.</contraindicationText>
<contraindicationGuidance/>
<contraindicatedVaccine>
<vaccineType>Chikungunya live attenuated vaccine, 0.5 mL, PF</vaccineType>
<cvx>317</cvx>
<beginAge/>
<endAge/>
</contraindicatedVaccine>
</contraindication>
<contraindication>
<observationCode>276</observationCode>
<observationTitle>Age is 60 years or older</observationTitle>
<contraindicationText>Do not vaccinate if the patient age is 60 years or older</contraindicationText>
<contraindicationGuidance/>
<contraindicatedVaccine>
<vaccineType>Chikungunya live attenuated vaccine, 0.5 mL, PF</vaccineType>
<cvx>317</cvx>
<beginAge>60 years</beginAge>
<endAge/>
</contraindicatedVaccine>
</contraindication>
</vaccine>
</contraindications>
<series>
<seriesName>Chikungunya Risk 1-dose series</seriesName>
<targetDisease>Chikungunya</targetDisease>
<vaccineGroup>Chikungunya</vaccineGroup>
<seriesAdminGuidance>CDC and FDA recently investigated five hospitalizations for cardiac (heart) or neurologic (nervous system) events following vaccination with IXCHIQ among older people. CDC and FDA advise people 60 years and older should not get the live-attenuated vaccine (IXCHIQ) until these additional reports are further investigated.</seriesAdminGuidance>
<seriesAdminGuidance>In general, vaccination of pregnant women should be deferred until after delivery. However, when the risk of infection is high (e.g., during an outbreak) and exposure cannot be avoided, a healthcare provider and pregnant woman should discuss the risks of chikungunya virus infection and the potential benefits and risks of vaccination</seriesAdminGuidance>
<seriesType>Risk</seriesType>
<equivalentSeriesGroups/>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>No</productPath>
<seriesGroupName>Increased Risk</seriesGroupName>
<seriesGroup>1</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>1</seriesPreference>
<minAgeToStart>12 years</minAgeToStart>
<maxAgeToStart/>
</selectSeries>
<indication>
<observationCode>
<text>Traveling to a country or territory where there is a chikungunya outbreak</text>
<code>271</code>
</observationCode>
<description>Administer to persons traveling to a country or territory where there is a chikungunya outbreak</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance>Areas with a current Chikungunya outbreak: https://www.cdc.gov/chikungunya/data-maps/index.html</guidance>
</indication>
<indication>
<observationCode>
<text>Traveling or moving to a country or territory without an outbreak but with elevated chikungunya risk for U.S. travelers if planning to stay for an extended period of time [e.g., 6 months or more]</text>
<code>272</code>
</observationCode>
<description>Persons traveling or moving to a country or territory without an outbreak but with elevated chikungunya risk for U.S. travelers if planning to stay for an extended period of time [e.g., 6 months or more] may consider vaccination</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance>Areas with an elevated risk for U.S. travelers: https://www.cdc.gov/chikungunya/data-maps/index.html</guidance>
</indication>
<indication>
<observationCode>
<text>Laboratory worker with potential for exposure to chikungunya virus</text>
<code>277</code>
</observationCode>
<description>Administer to laboratory workers with potential for exposure to chikungunya virus</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>12 years - 4 days</absMinAge>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval/>
<allowableInterval/>
<preferableVaccine>
<vaccineType>Chikungunya live attenuated vaccine, 0.5 mL, PF</vaccineType>
<cvx>317</cvx>
<beginAge>18 years</beginAge>
<endAge>60 years</endAge>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>Chikungunya, VLP, recombinant, 0.8 mL, PF</vaccineType>
<cvx>329</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.8</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>Chikungunya live attenuated vaccine, 0.5 mL, PF</vaccineType>
<cvx>317</cvx>
<beginAge>18 years - 4 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>Chikungunya, VLP, recombinant, 0.8 mL, PF</vaccineType>
<cvx>329</cvx>
<beginAge>12 years - 4 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
</antigenSupportingData>
